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Neglected tropical diseases (NTDs) have
been recently identified as significant public
health problems in Texas and elsewhere in
the American South. A one-day forum on the
landscape of research and development and
the hidden burden of NTDs in Texas
explored the next steps to coordinate advo-
cacy, public health, and research into a
cogent health policy framework for the
American NTDs. It also highlighted how
U.S.-funded global health research can serve
to combat these health disparities in the
United States, in addition to benefiting
communities abroad.
Introduction
While neglected tropical diseases
(NTDs) are usually thought of as a group
of chronic parasitic and related infections
affecting those living on US$1–2 per day
in the poorest developing countries [1,2],
there is increasing awareness that the
NTDs also strike pockets of impoverished
people who live in wealthy countries,
including the United States, Canada,
many European nations, and Australia
[3–9]. The NTDs found among the poor
in wealthy countries often differ from
those found predominantly in low- and
middle-income countries (LIMCs), but
they nonetheless exhibit many of the same
features, including their chronicity and
adverse impact on child development,
pregnancy outcome, and worker produc-
tivity [4–6,10]. Moreover, the NTDs in
the U.S. disproportionately affect people
of color and indigenous populations, much
as they also do in the Latin American and
Caribbean region [3,11]. In this sense, the
NTDs are important contributors to
American health disparities.
Today, an estimated 46 million Amer-
icans live below the poverty line (defined
as US$22,314 for a family of four in the
U.S.), including approximately 20 mil-
lion existing in so-called ‘‘extreme pov-
erty’’ (50% or less than the poverty line)
[12,13]. Some of the largest numbers of
people who live below the U.S. poverty
line live in Texas [13–15]. Roughly one
in five Texans (approximately 4–5 mil-
lion people) currently lives below the
poverty line, with South Texas counties
exhibiting some of the highest rates of
poverty in the U.S. [13–15]. In June of
2012, the nonprofit education and advo-
cacy organization Research!America, to-
gether with the American Society of
Tropical Medicine and Hygiene
(ASTMH) and several institutions of the
Texas Medical Center including the
Sabin Vaccine Institute, Texas Chil-
dren’s Hospital Center for Vaccine
Development, and the National School
of Tropical Medicine at Baylor College
of Medicine, sponsored a one-day forum
that explored global health research,
social determinants of health, and advo-
cacy to highlight the impact of NTDs in
Texas and elsewhere on the Gulf Coast
and in the American South. The forum
proposed several key steps needed to generate
advocacy strategies for the development of
evidence-based policies to address these
diseases both regionally and nationally.
Overview of the NTDs in Texas
and the American South
The major NTDs in Texas and other
areas of the American South are listed in Box
1. Among their common features is the
observation that most of these conditions
cause chronic disabilities, which dispropor-
tionately affect people living in extreme
poverty [3,5,13–15]. Another key feature is
that NTDs are important examples of health
disparities mostly affecting people of color,
particularly African American and Hispanic
minorities, largely because of the poverty link
[3,5,13–15].
Neglected Parasitic Infections
Among the parasitic infections, Chagas
disease (American trypanosomiasis caused
by Trypanosoma cruzi infection) received
renewed attention in 2012 based on
recently published estimates of large
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numbers of people infected in the Western
Hemisphere, including the high preva-
lence rates among pregnant women and
subsequent maternal-to-child transmission
[16,17]. Of note, the first reported case of
mother-to-child transmission in the U.S.
was announced on July 6, 2012 by the
Centers for Disease Control and Preven-
tion (CDC) [18]. The CDC estimates that
300,000 cases of Chagas disease are found
in the U.S. [19], whereas other investiga-
tors have suggested that almost as many
cases occur in Texas alone [20]. Several
kissing bug vector species are widespread
in Texas and capable of transmitting T.
cruzi; a significant percentage of these
vectors are polymerase-chain-reaction
(PCR) positive for T. cruzi [19,21]. In
South Texas, a high percentage of dogs,
which are natural hosts, are also infected
with T. cruzi [22], and a risk map for
humans acquiring Chagas disease in
Texas has been developed [21]. However,
the extent to which T. cruzi transmission to
humans actually occurs in the state is
unknown [14]. There is an urgent need to
increase surveillance for human T. cruzi
infection in the region, possibly through
seroprevalence studies, as well as for
studies that attempt to document the
extent of autochthonous transmission and
mother-to-child transmission. In this sense,
we are still at the ‘‘tip of the iceberg’’ in
terms of our understanding of the epide-
miology of Chagas disease in Texas and
elsewhere in the American South. An
alternative metaphor is that we have only
seen the ‘‘ears of the armadillo’’ (similar to
the ears of the hippopotamus metaphor
sometimes used for malaria in Africa),
referring to the nine-banded armadillo
(Dasypus novemcinctus), which is native to
Texas (Figure 1).
Information is also scant for several
other key NTDs in Texas. As with Chagas
disease, these NTDs appear to be wide-
spread in different areas of the state, but
supporting surveillance and transmission
studies are either sporadic or missing.
Cutaneous leishmaniasis (CL) is another
vector-borne parasitic protozoan infection,
caused by Leishmania spp. and transmitted
by sand flies of the genus Lutzomyia.
Human cases of autochthonous CL caused
by Leishmania mexicana infection have been
recognized in Texas, primarily in the
south-central region, since 1903 [23]. In
2008, nine cases were reported in northern
Texas, not far from the Dallas-Fort Worth
area [24]. There are several important
animal reservoirs of Leishmania spp. in the
Americas. In Latin America, rodents serve
as an important animal reservoir for L.
mexicana, and the Southern Plains woodrat
has been implicated in Texas [23] and
elsewhere in the southern U.S. Wide-
spread infection of foxhounds in the U.S.
with visceralizing L. infantum is also of
concern, but the true extent of veterinary
and human transmission in Texas and the
rest of the U.S. is largely unknown [25]. A
recent modeling study suggests that the
range of reservoirs and sand fly vectors for
CL is likely to expand deeper into the
U.S., possibly in association with climate
change [26], and thus, a northward
expansion of CL infection in humans is
conceivable.
Among the helminthic infections, neu-
rocysticercosis (NCC) is now a major cause
of epilepsy in Texas [27]. Most of the
recent cases of NCC are believed to have
been imported through immigration from
Latin America [27], but autochthonous
transmission still remains a possibility.
Toxocariasis (Toxocara canis and Toxocara
cati infection) is widespread in the Amer-
ican South, particularly among African
American and Hispanic minority popula-
tions [28]. A covert form of this NTD has
been linked to asthma and developmental
delays [29], but the prevalence of toxoca-
riasis in Texas and its potential contribu-
tion to chronic sequelae in the state have
not been accurately determined.
Neglected Viral and Bacterial
Infections
West Nile virus (WNV) infection, a
mosquito-transmitted arbovirus infection,
emerged in Houston, Texas in 2002 [30],
where it occurs more commonly among
people living in proximity to bayous lined
with vegetation and other bodies of
stagnant or slow-moving water [31]. Texas
experienced a historic peak in WNV cases
in 2012 affecting several areas of the state
[32]. Like other vector-borne NTDs,
WNV infection has been linked to poverty
and its associated conditions [13,33,34]. A
study in Houston in 2004 found that 7% of
homeless people were positive for WNV
infection, and that seroprevalence rose to
17% for those who did not seek shelter at
night [34]. Risk factors for severe disease
from WNV infection include hyperten-
sion, diabetes, and alcohol and substance
abuse [35–39], which are all chronic
morbidities that often go untreated in
marginalized populations. In Texas and
elsewhere, WNV infection was recently
identified as an emerging etiologic agent of
chronic renal disease and kidney failure
[40].
Dengue emerged in South Texas in
1980, with additional outbreaks recog-
nized in 1999 and 2005, and where
conditions related to poverty also repre-
sent major risk factors for infection
[41,42]. Studies to determine the preva-
lence of dengue virus infection among
residents of city-pairs on the U.S.-Mexico
border have shown much higher rates of
acute and past infection in Texas than
would have been anticipated based on
how infrequently the disease is recognized
and reported [41–43]. In 2004 and 2005,
recently contracted dengue virus infections
were found among an estimated 2–4% of
the residents of Brownsville, Texas, com-
pared to 7–32% of residents of Mata-
moros, Mexico, with part of the difference
having been ascribed to socioeconomic
factors [41,42]. The under-recognition of
an ongoing dengue outbreak in the U.S.
was recently highlighted in Key West,
Florida [44,45] and emphasizes the need
for better surveillance and education of
clinicians about NTDs in the U.S. Severe
dengue has occurred in the continental
U.S. and is always a concern where
frequent dengue virus infections occur.
Preliminary studies indicate that dengue
may have already emerged in Houston
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(unpublished data). International air travel
increases the risk for importation of
dengue virus and possible outbreaks [46],
an especially salient factor given Houston’s
role as a major international air travel hub
and the presence of the mosquito vector.
Among the major bacterial infections,
murine typhus (Rickettsia typhi infection,
transmitted by cat fleas) is emerging in
South Texas [47]. An important evolving
scenario lies at the interface of infectious
diseases and the pandemic of chronic
disease. Substantial evidence documents
type 2 diabetes as the most important
major risk factor for tuberculosis (TB)
along the Texas border with Mexico
[48,49], increasing the risk of active TB
three-fold. Similar observations have now
been made in TB high burden countries
across the globe [50]. Altered gene
expression in the host and altered immune
responses to several other pathogens in
diabetes have been identified [51–54].
Studies conducted in South Texas were
instrumental in uncovering the relation-
ship between TB and diabetes such that
additional studies in Texas might help in
determining if similar relationships exist
for other neglected diseases. The interac-
tion between TB and type 2 diabetes
illustrates how a neglected disease may
interface with a chronic noncommunica-
ble disease (CNCD). Some data suggest
that the NTDs themselves manifest much
like the CNCDs with respect to their
chronic morbidities [55], and may cer-
tainly account for a hidden burden of
CNCD-related morbidity [56].
Advancing Public Health in the
Region
So far we have only seen the ears of the
armadillo with respect to the full extent of
the NTD problem in Texas. Tragically,
minimal surveillance data exist for all of
the NTDs highlighted above [13]. This
situation is particularly alarming given
that the NTDs disproportionately affect
vulnerable populations, especially chil-
dren, pregnant women, people living in
poverty, people of color, and indigenous
populations [4–8]. To that end, there is an
urgent need to identify the critical public
health gaps and address the specific needs
in Texas and the adjacent regions. Para-
doxically, within the U.S. biomedical
community there has been a diminished
emphasis on population-based investiga-
tions to determine disease burden and
epidemiology in favor of laboratory and
clinical investigations, which are thought
to be more amenable to receiving support
from the U.S. National Institutes of Health
and other funding agencies.
Several types of studies must be under-
taken [13]. For many of the major NTDs,
there is the need to establish robust
estimates of their burden in the U.S.
through population-based prevalence
and/or incidence studies in Texas and
other vulnerable areas, coupled with
epidemiologic studies to determine modes
of disease transmission. For instance, while
we believe Chagas disease is widespread in
South Texas, we have only a modest
evidence base to support this premise, and
we know even less about the percentage of
human cases transmitted within the state
from indigenous vectors and animal res-
ervoirs [14]. Such information is needed to
better understand the dynamics of disease
transmission and the potential risk of
acquiring this disease. For other NTDs,
such as dengue, toxocariasis, and WNV,
the factors responsible for urban transmis-
sion need to be better delineated. Given
that many of these diseases are vector-
borne, studies about the prevalence and
competence of the relevant hosts and
reservoirs are also needed. Collection of
this data, which will require work in
northern Mexico, may be hindered be-
cause of the ongoing unrest in the region.
There is a need for better mapping and to
conduct geographic information system/
remote sensing–based research to produce
next generation risk maps for acquiring
the NTDs. We need to better understand
the exact role of poverty in NTD trans-
mission. Why exactly is poverty a major
risk factor for most of the NTDs in the
U.S.? Inadequate housing with lack of
indoor screens and air-conditioning, as
well as external degradation linked with
absent sanitation, garbage pick-up, or (in
the case of WNV virus) neglected swim-
ming pools [33] may provide part of the
answer, but it would be extremely useful to
understand the scientific basis for the link
between poverty and disease [13]. Some of
these factors might be addressed, at least
partially, through more outreach by the
scientific community to the local citizenry
and community-based organizations. For
Figure 1. The ears of the armadillo. http://en.wikipedia.org/wiki/File:Nine-banded_Armadillo.jpg, accessed August 16, 2012.
doi:10.1371/journal.pntd.0002021.g001
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many of the NTDs, case management and
treatment algorithms are still at a rudi-
mentary stage. However, once estimates of
disease burden are established and popu-
lations are identified in the NTD-endemic
regions of the U.S., there might be greater
interest in conducting treatment and
management studies in controlled clinical
settings.
Currently, few if any prevention strate-
gies for NTDs are in place in Texas or
surrounding states. One exception is an
aggressive mosquito-control initiative in
Houston and surrounding areas of Harris
County to reduce the Culex mosquito
population as a means to lower WNV
transmission [57]. For all the NTDs,
prevention strategies should be defined,
the effectiveness of these prevention strat-
egies determined through outcome studies,
and their economic and public health
value modeled, as has been done for many
global health prevention strategies to fight
HIV/AIDS, malaria, and other diseases.
It is unclear whether public funds will
be available anytime soon to support such
public health and prevention studies or to
foster community involvement to address
the NTD problem in the U.S. There is a
dearth of available funding for partner-
ships with federal (e.g., the CDC), state,
and local health agencies for this purpose.
One proposal mentioned at the forum is to
consider supporting partnering opportuni-
ties between major research universities in
Texas (e.g., Baylor College of Medicine,
University of Texas, Texas A&M Univer-
sity, Texas Tech University, University of
Houston, and Rice University) and local
universities near the Mexican border (e.g.,
University of Texas-Pan American) to
build local capacity for epidemiologic
research. This approach is similar to a
U.S. National Institutes of Health Fogarty
International Center–sponsored ‘‘twin-
ning’’ initiative in Africa known as MEPI
(Medical Education Partnership Initiative)
[58]. Possibly, such an approach could
become an initiative of The Academy of
Medicine, Engineering, and Science of
Texas (TAMEST).
Simultaneously, there is a substantial
need for workforce development and
capacity building within the state to
enhance laboratory and diagnostic testing
for the NTDs. Many of the current
diagnostic assays for conditions such as
Chagas disease, cysticercosis, toxocariasis,
and the arboviral infections, among oth-
ers, are not widely or easily available,
especially in the impoverished areas of
South Texas where the needs are the
greatest. In some cases, especially for the
neglected viral infections, special contain-
ment facilities may be required. Capacity
building is needed to train public health
officials for the unique needs of surveil-
lance and control of NTDs, including the
use of appropriate technology for these
conditions. Such efforts include the need
to train entomologists or vector biologists
in the identification and control of the
suspected vector. Physicians, nurse practi-
tioners, and other health care providers
must be trained to recognize, manage, and
treat these diseases. The new National
School of Tropical Medicine in Houston is
potentially positioned to work in close
partnership with state and local health
agencies in this regard [13,59]. The
existing network of University of Texas
public health schools and other public
health institutions such as the Pan Amer-
ican Health Organization (PAHO) could
also enhance training and other collabo-
rations. Previously, PAHO, together with
a network of public health laboratories,
was highly effective in coordinating efforts
to eliminate polio, measles, rubella, and
other infections in the Latin American and
Caribbean region [60].
Advancing Research and
Development (R&D) for New
Control Tools
In tandem with expanded public health
measures, there is a pressing need to
develop better control tools for the NTDs,
including new drugs, vaccines, diagnostics,
insecticides, and mathematical and com-
putational models. For example, for Cha-
gas disease, there is an urgent need for
new biomarkers to follow disease progres-
sion [61]. The toxicities and other prob-
lems inherent in the only two existing
medicines currently used to treat Chagas
disease (benznidazole and nifurtimox)
have been highlighted, prompting a search
for alternative drugs and new vaccines
[17,62–64]. We also need new tools to
assess vector exposure and transmission of
Chagas disease and leishmaniasis. A vac-
cine for leishmaniasis (including a trans-
mission blocking vaccine from dogs) has
also been proposed [65] and shown to be
cost-effective for VL [66]. For NCC, there
is a need for more sensitive diagnostic tests
and biomarkers, especially for patients
with single brain lesions, which have a
high false-negative rate [27]. For WNV
infection, there is a need to better
delineate the role of the virus as a cause
of renal disease and to evaluate possible
antiviral therapeutic interventions and
possibly a vaccine [40,67]. For dengue,
several prototype vaccines are under devel-
opment by a number of pharmaceutical
companies, as well as new antiviral drugs
[68]. Of interest is the development of a new
humanized mouse model for dengue, which
may accelerate such product development
[69]. For all of the vector-borne NTDs, at-
risk populations would benefit from improved
vector and reservoir control strategies and
integrated management. Mosquito control
methods could benefit prevention efforts for
multiple NTDs in Texas, including dengue,
WNV, and Saint Louis encephalitis. We
recognize the complexities of implementing
vector and reservoir control measures and
their integrated management; however, each
of these control tools can be modeled to
determine when they may be cost-effective or
highly cost-effective. Some may even prove to
be cost-saving (economically dominant),
when an intervention actually saves money
(in addition to having health benefits)
compared to the status quo. Many of these
products may not be financially remunerative
and would need to be developed in the
nonprofit sector, possibly through similar
models as those used by product develop-
ment partnerships [70]. Finally, and as
pointed out above, the finding of syndemic
tuberculosis and type 2 diabetes in Texas
should also prompt the search for additional
links between NTDs and CNCDs. Such
research could play an important role in
improving health interventions for these
conditions.
Strategies for Advocacy: The
Way Forward
Given the overall dearth of information
currently available on the NTDs in Texas
and the rest of the U.S., it is challenging to
formulate useful policy guidelines that are
fully evidence-based. Yet, without a coor-
dinated plan of advocacy and education
on these conditions, public health–directed
research and development efforts will not
increase, leaving us in the same situation
of insufficient data needed to make
informed policy decisions, and insufficient
interventions to address known threats. It
is also true that formulating a successful
advocacy strategy faces an uphill battle.
NTDs have already fallen through the
cracks between the two large international
public health movements inaugurated in
this first part of the twenty-first century:
twelve years of global health outreach
beginning in 2000 with the launch of the
Millennium Development Goals and the
more recent CNCD advocacy effort
launched at the United Nations last year.
Domestically, while there has been in-
creased attention to health disparities in
the U.S. during the landmark health care
reform measures over the past two years,
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the American NTDs, an important con-
tributor to this disparity, have been barely
mentioned. To that point, the first summit
on NTDs in the U.S. held in Washington,
D.C. more than two years ago [6] helped
to stimulate the introduction of the
‘‘Neglected infections of impoverished
Americans act of 2011’’ (H.R. 528) as a
means to encourage U.S. health officials to
collect essential information on some of
the major diseases highlighted above
[13,71]. However, it is unclear whether
this effort will be implemented.
There are several possible reasons why
the NTDs in the U.S. have not risen
higher on the domestic or global health
policy agenda, including the fact that these
diseases often have complicated names,
ecologies, and modes of transmission. It is
also likely that NTDs face the same
funding obstacles as other diseases that
disproportionately affect people of color
and those living in extreme poverty.
During the Texas forum, it was noted
that if these conditions were affecting
people living in wealthy suburbs, they
might have already gained substantial
media attention or even possibly become
the subject of congressional hearings.
Instead, the U.S. NTDs remain ‘‘forgotten
diseases of forgotten people’’ [72]. In this
sense, the American NTDs put to the test
the nation’s commitment to a core prin-
ciple of public health: an issue of equitable
benefits and justice for all populations. But
beyond the moral implications, because
these diseases respect no border or neigh-
borhood boundaries, even skeptics should
understand that tackling diseases of pov-
erty now will confer the pragmatic benefit
of dramatically reducing the risk of spread.
Simply put, there is an urgent need to
bolster the evidence base for defining the
scope and impact of the NTDs in Texas
and surrounding states. In Latin America,
careful disease burden assessments and
cost-effectiveness studies of vaccination
and other intervention strategies helped
to introduce new vaccines against key
diseases [73]. Many of these activities are
coordinated through PAHO’s ProVac
Initiative [73]. Ideally, funds would be
made available to launch a similar initia-
tive for NTDs in the U.S., but instead we
are faced with a ‘‘chicken and egg’’
situation. We don’t have the necessary
funding, political will, or infrastructure to
support data collection for surveillance,
transmission, and disease burden studies,
much less the investment needed to
produce new interventions. Given these
realities, the need for a comprehensive
advocacy strategy that factors in these
innovative strategies is essential if we are to
make a real difference in the lives of
‘‘forgotten people’’ in Texas and else-
where. However, without more public
health evidence and examples of the
benefits of new tools, effective advocacy
strategies are extremely difficult to formu-
late.
Despite the hurdles, we must persevere.
Research!America, ASTMH, and some of
the key Texas universities and institutions
can take meaningful first steps by embark-
ing on media outreach, together with
science-policy discussions in Washington,
D.C., and by engaging the Texas delega-
tion of the U.S. Congress and key
congressional caucuses (e.g., the Black
and Hispanic Caucuses and the Malaria-
NTD Caucus). It is important that we take
every opportunity to obtain the data
required to make informed decisions and
engage in targeted advocacy. Where
appropriate, the CDC and other re-
search-oriented institutions or organiza-
tions should present their latest epidemio-
logic and disease burden data offering an
informed perspective on both the domestic
and international front. With a coordinat-
ed effort of multiple stakeholders both
within and outside of U.S. government, we
can overcome ignorance and apathy and
combat NTDs as a compelling and urgent
health disparities issue, an emblematic
public health imperative, and an insidious
global health threat.
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